Emergent BioSolutions Inc. 8-K

What Happened

• Emergent BioSolutions Inc. announced its financial and operating results for the quarter and the year ended December 31, 2025 via a press release dated February 26, 2026. The press release is furnished as Exhibit 99.1 to the Form 8‑K (Item 2.02).
• The company will host a conference call to discuss those results and will post earnings presentation slides on its website; the slides are furnished as Exhibit 99.2 to the Form 8‑K (Item 7.01). The Form 8‑K was signed by Richard S. Lindahl, EVP and Chief Financial Officer, on February 26, 2026.

Key Details

• Filing date: February 26, 2026 (Form 8‑K filed with the SEC).
• Reporting period: quarter and fiscal year ended December 31, 2025.
• Materials: Press release (Exhibit 99.1) and Earnings Call Slides (Exhibit 99.2) are furnished with the 8‑K and will also be posted at www.emergentbiosolutions.com.
• Regulatory note: The furnished materials are disclosed under Regulation FD and are not deemed “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters

• This 8‑K signals the company has released its latest earnings and operational results; investors should review the press release and slides for revenue, earnings, guidance, and any changes to business outlook.
• The conference call and slides provide management commentary and detail that can influence short‑term share movement and help investors assess performance trends.
• Because the materials are furnished (not “filed”), they are publicly available but carry specific legal treatment under SEC rules; primary sources are the press release, the earnings slides, and the 8‑K on the SEC website.